Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-34. (Canceled)

35. (Previously Presented) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a composition comprising:

(a) a WT1 polypeptide consisting of an immunogenic portion of a native WT1, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144; and

(b) a physiologically acceptable carrier or excipient;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

36. (Canceled)

37. (Previously Presented) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a composition comprising:

(a) a WT1 polypeptide consisting of an immunogenic portion of a native WT1, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144; and

(b) a non-specific immune response enhancer;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

38.-62. (Canceled)

63. (Currently Amended) A method for stimulating and/or expanding T cells, comprising contacting T cells with a WT1 polypeptide ~~or a polynucleotide encoding a WT1 polypeptide~~, wherein said WT1 polypeptide consists of an immunogenic portion of native WT1, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144, under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

64. (Previously Presented) A method according to claim 63, wherein the T cells are present within bone marrow, peripheral blood or a fraction of bone marrow or peripheral blood.

65. (Previously Presented) A method according to claim 64, wherein the bone marrow, peripheral blood or fraction is obtained from a patient afflicted with a malignant disease associated with WT1 expression.

66. (Previously Presented) A method according to claim 64, wherein the bone marrow, peripheral blood or fraction is obtained from a mammal that is not afflicted with a malignant disease associated with WT1 expression.

67. (Previously Presented) A method according to claim 63, wherein the T cells are cloned prior to expansion.

68. (Currently Amended) A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a composition comprising:

(a) ~~one or more of:~~

~~(i)~~ a WT1 polypeptide; ~~or~~

~~(ii) a polynucleotide encoding a WT1 polypeptide;~~

wherein said WT1 polypeptide consists of an immunogenic portion of native WT1, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144; and

(b) a physiologically acceptable carrier or excipient;

and thereby stimulating and/or expanding T cells in a mammal.

69. (Currently Amended) A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a composition comprising:

(a) ~~one or more of:~~

~~(i) a WT1 polypeptide; or~~

~~(ii) a polynucleotide encoding a WT1 polypeptide;~~

wherein said WT1 polypeptide consists of an immunogenic portion of native WT1, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144; and

(b) a non-specific immune response enhancer;

and thereby stimulating and/or expanding T cells in a mammal.

70.-103. (Canceled)

104. (Currently Amended) The method of claim 35 wherein said physiologically acceptable carrier comprises a biodegradable microsphere.

105. (Previously Presented) The method of claim 37 wherein said non-specific immune response enhancer is selected from the group consisting of alum-based adjuvants, oil based adjuvants, nonionic block copolymer-based adjuvants, dimethyl dioctadecyl ammoniumbromide based adjuvants, Ribi Adjuvant system based adjuvants, QS21, saponin based adjuvants, muramyl dipeptide based adjuvants, human complement based adjuvants, immune stimulating complex based adjuvants, inactivated toxins, and attenuated infectious agents.

106. (Currently Amended) The method of claim 68 wherein said physiologically acceptable carrier comprises a biodegradable microsphere.

107. (Previously Presented) The method of claim 69 wherein said non-specific immune response enhancer is selected from the group consisting of alum-based adjuvants, oil based adjuvants, nonionic block copolymer-based adjuvants, dimethyl dioctadecyl ammoniumbromide based adjuvants, Ribi Adjuvant system based adjuvants, QS21, saponin based adjuvants, muramyl dipeptide based adjuvants, human complement based adjuvants, immune stimulating complex based adjuvants, inactivated toxins, and attenuated infectious agents.

108. (Previously Presented) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a composition comprising:

(a) a WT1 polypeptide consisting of an immunogenic portion of a native WT1, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144; and

(b) a physiologically acceptable carrier comprising a microsphere; and

(c) a non-specific immune response enhancer comprising a Ribi Adjuvant system based adjuvant;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

109. (Currently Amended) A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a composition comprising:

(a) ~~one or more of:~~

~~(i) a WT1 polypeptide; or~~

~~(ii) a polynucleotide encoding a WT1 polypeptide;~~

wherein said WT1 polypeptide consists of an immunogenic portion of native WT1, wherein the immunogenic portion consists of the consecutive amino acids of SEQ ID NO:144;

(b) a physiologically acceptable carrier comprising a microsphere; and

(c) a non-specific immune response enhancer comprising a Ribi Adjuvant system based adjuvant;

and thereby stimulating and/or expanding T cells in a mammal.